Fanotaprim

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC 50 s of 1.57 and 308 nM for tg DHFR ( Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis. In Vitro Fanotaprim shows parasiticidal and antiproliferative effects with EC 50 s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively. Fanotaprim shows ability to inhibit the growth of T. gondii strains in vitro with EC 50 s ranging 7.6~ 29.8 nM (GT1, ME49, CTG, RUB and VAND). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) shows highly effective in control of acute infection by highly virulent strains of T. gondii in the murine model . Fanotaprim (1mg/kg; i.v; mouse) shows C L , V d , and t 1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively . Fanotaprim (0.83 mg/kg; p.o; mouse) shows F, C max , T max , and AUC 0-last of 47.3%, 178 ng/mL, 0.05 hours and 750 ng h/mL, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CD-1female mice (murine model of acute toxoplasmosis) Dosage: 1-10 mg/kg Administration: p.o.; daily; beginning on day 1 through day 7 Result: Mice were monitored for survival for 30 days within termittent IVIS monitoring. At doses of 10 mg/kg Fanotaprim, q.d. or b.i.d. for 7 days, yielded 100% survival for 30 days.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet